Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Akt activation is involved in P2Y12 receptor-mediated chemotaxis of microglia.

Authors: Irino, Yasuhiro  Nakamura, Yasuko  Inoue, Kazuhide  Kohsaka, Shinichi  Ohsawa, Keiko 
Citation: Irino Y, etal., J Neurosci Res. 2008 May 15;86(7):1511-9. doi: 10.1002/jnr.21610.
Pubmed: (View Article at PubMed) PMID:18183622
DOI: Full-text: DOI:10.1002/jnr.21610

Microglia play a variety of significant roles in the central nervous system (CNS), and in one of those roles they undergo morphological change in response to neural injury and migrate to the injured region. We previously reported that ATP/ADP promotes microglial chemotaxis via the Gi/o-coupled P2Y12 receptor; however, the intracellular signaling underlying P2Y12-receptor-mediated microglial chemotaxis is not fully understood. In this study, we examined the role of phospholipase C (PLC) and calcium signaling in ADP-induced microglial chemotaxis. A PLC inhibitor, U73122, significantly suppressed the chemotaxis and completely blocked the ADP-evoked intracellular calcium response, and a calcium chelator, BAPTA-AM, inhibited the chemotaxis. These results indicate that ADP-induced microglial chemotaxis is regulated by a PLC-mediated calcium pathway. ADP stimulation induced Akt phosphorylation in microglia, and the phosphorylation was inhibited by a P2Y12 receptor antagonist, AR-C69931MX. The Akt phosphorylation was blocked by U73122 and BAPTA-AM as well as by a phosphatidylinositol 3-kinase (PI3K) inhibitor, wortmannin, and inhibition of the Akt activation resulted in failure of chemotaxis. These results indicate that Akt activation is dependent on the PI3K pathway and a PLC-mediated increase in intracellular calcium and suggest that Akt activation is involved in ADP-induced microglial chemotaxis.


Gene Ontology Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 13673786
Created: 2018-06-23
Species: All species
Last Modified: 2018-06-23
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.